Skip to main content

Advertisement

Log in

Next-generation, genome- and mutational landscape heterogeneity-based novel biomarkers for personalized neoadjuvant treatment and laparoscopic rectal cancer resection

  • Letter to the Editor
  • Published:
Surgical Endoscopy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Fleming FJ, Påhlman L, Monson JR (2011) Neoadjuvant therapy in rectal cancer. Dis Colon Rectum 54(7):901–912

    Article  PubMed  Google Scholar 

  2. Hawkes EA, Cunningham D, Tait D, Brown G, Chau I (2011) Neoadjuvant chemotherapy alone for early-stage rectal cancer: an evolving paradigm? Semin Radiat Oncol 21(3):196–202

    Article  PubMed  Google Scholar 

  3. Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726

    Article  PubMed  CAS  Google Scholar 

  4. Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545

    Article  PubMed  CAS  Google Scholar 

  5. Denost Q, Laurent C, Paumet T, Quintane L, Martenot M, Rullier E (2012) Laparoscopic surgery for rectal cancer: preoperative radiochemotherapy versus surgery alone. Surg Endosc 26(7):1878–1883

    Article  PubMed  Google Scholar 

  6. Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10(4):473–476

    Article  PubMed  Google Scholar 

  7. Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555

    Article  PubMed  CAS  Google Scholar 

  8. Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350

    Article  PubMed  Google Scholar 

  9. Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651

    Article  PubMed  Google Scholar 

  10. Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22(5):1402–1404

    Article  PubMed  Google Scholar 

  11. Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696

    Article  PubMed  Google Scholar 

  12. Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406

    Article  PubMed  Google Scholar 

  13. Nikiteas N, Roukos D, Kouraklis G (2011) Robotic versus laparoscopic surgery: perspectives for tailoring an optimal surgical option. Expert Rev Med Devices 8(3):295–298

    Article  PubMed  Google Scholar 

  14. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP, MRC COIN Trial Investigators (2011) Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377(9783):2103–2114

    Article  PubMed  CAS  Google Scholar 

  15. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307(13):1383–1393

    Article  PubMed  CAS  Google Scholar 

  16. Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Pers Med 7(4):347–350

    Article  CAS  Google Scholar 

  17. Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586

    Article  PubMed  Google Scholar 

  18. Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043

    Google Scholar 

  19. Roukos DH (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 11(2):81–92

    Google Scholar 

  20. Roukos DH (2011) Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol 18(1):12–15

    Google Scholar 

  21. Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745

    Google Scholar 

  22. Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715

    Google Scholar 

  23. Roukos DH (2011) Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics 12(5):695–698

    Google Scholar 

  24. Roukos DH (2011) Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices 8(2):123–126

    Google Scholar 

  25. Roukos DH (2011) “Big” Science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn 11(2):123–126

    Google Scholar 

  26. Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28(17):e279–e280; author reply e282–e283

    Google Scholar 

  27. Roukos DH (2011) Translating epigenetics into an anticancer drug pipeline for solid tumors. Expert Rev Med Devices 8(4):409–413

    Google Scholar 

  28. Roukos DH (2011) Chromatin: a key player in complex gene regulation and future cancer therapeutics. Epigenomics 3(4):395–399

    Google Scholar 

  29. Roukos DH (2012) Spatiotemporal individual genome code-lifestyle network: revolutionizing personal diagnostics. Expert Rev Mol Diagn 9(3):215–218

    Google Scholar 

  30. Roukos DH (2012) Differential signalling transduction networks for clinical robustness. Expert Rev Proteomics 9(2):111–114

    Google Scholar 

  31. Roukos DH (2012) Biotechnological, genomics and systems-synthetic biology revolution: redesigning genetic code for a pragmatic systems medicine. Expert Rev Med Devices 9(2):97–101

    Google Scholar 

  32. Roukos DH (2012) Disrupting cancer cells’ biocircuits with interactomebased drugs: is ‘clinical’ innovation realistic? Expert Rev Proteomics 9(4):349–353

    Google Scholar 

Download references

Disclosure

Christof Hottenrott has no conflict of interest or financial ties to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christof Hottenrott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hottenrott, C. Next-generation, genome- and mutational landscape heterogeneity-based novel biomarkers for personalized neoadjuvant treatment and laparoscopic rectal cancer resection. Surg Endosc 27, 1441–1443 (2013). https://doi.org/10.1007/s00464-012-2570-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00464-012-2570-3

Keywords

Navigation